Intensity-Modulated or Proton Beam Radiation Therapy Together with or without Cisplatin in Treating Patients with Stage III-IVB Paranasal Sinus and Nasal Cavity Cancer

Inclusion Criteria

• Biopsy proven, within 16 weeks prior to study entry, sinonasal adenoid cystic carcinoma, adenocarcinoma, mucoepidermoid carcinoma, squamous cell carcinoma, including sinonasal carcinoma, sinonasal undifferentiated carcinoma, Schneiderian carcinoma, myoepithelial carcinoma, undifferentiated carcinoma, esthesioneuroblastoma, or melanoma American Joint Committee on Cancer (AJCC) 7th edition stage III - IVA/B tumors, or with skull base or intracranial extension; pathology must be confirmed by review at the treating institution
• Patients with biopsy proven locally advanced sinus, nasal cavity, hard palate, soft palate, major or minor salivary gland tumors, or lacrimal apparatus, with nasal cavity, sinus, auditory canal, or skull base involvement are eligible
• Eastern Cooperative Oncology Group (ECOG) performance status 0 – 1 or Karnofsky performance status >= 70
• All patients must undergo pre-treatment evaluation of tumor extent prior to study entry through imaging studies and clinical examinations, including computed tomography (CT) and/or magnetic resonance imaging (MRI) of skull base, brain and neck within 28 days prior to study entry; physical examination +/- nasal endoscopy within 28 days prior to study entry; and CT of the chest within 60 days prior to study entry
• Nutritional and general physical condition must be considered compatible with the proposed radiation +/- chemotherapy treatment
• Signed study-specific informed consent prior to study entry
• Absolute neutrophil count >= 1,000/mm^3, within 14 days prior to study entry
• Platelets >= 75,000/mm^3, within 14 days prior to study entry
• Total bilirubin =< 2 x upper limit of normal (ULN), within 14 days prior to study entry
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULN, within 14 days prior to study entry
• Serum creatinine =< 2 mg/dl or creatinine clearance >= 40 ml/min (creatinine clearance calculated per Cockroft-Gault formula or by 24-hour urine collection), within 14 days prior to study entry
• Patients may receive radiation alone if the above criteria is not met
• Patients with symptomatic peripheral motor or sensory neuropathy >= grade 2 at baseline will receive radiation therapy alone
• Patients with >= grade 3 sensorineural hearing loss at baseline may receive radiation alone or radiation with carboplatin
• Patients with adenoid cystic carcinoma, adenocarcinoma, mucoepidermoid carcinoma, myoepithelial carcinoma who have undergone gross total resection who refuse chemotherapy may receive radiation alone
• Age 18 or above
• No active alcohol addiction that will interfere with participation in this study, as assessed by medical caregiver
• Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to study entry
• Patients must be willing to receive follow-up care for a minimum of 5 years after treatment at participating institution(s) and annual visits unless it is too difficult to return to participating institution for follow-up care; in that event, patients must be willing to have outside medical information released in order to track the results of treatment

Exclusion Criteria

• Participants may not be receiving any other study agents, and may not have received any other investigational agents within 6 months prior to study entry
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin for patients who will receive chemotherapy
• Evidence of distant metastases or distant leptomeningeal metastases at the time of diagnosis
• Previous irradiation for head and neck tumor, skull base, or brain tumors
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for at least 3 months thereafter; pregnant women are excluded from this study because cisplatin is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cisplatin, breastfeeding should be discontinued if the mother is treated with cisplatin
• Individuals with a history of a different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; individuals with the following cancers are eligible if diagnosed and treated for cure within the past 2 years: cervical cancer in situ, carcinoma in situ of the breast, and basal cell or squamous cell carcinoma of the skin
• Patients with a radiosurgery boost or fractionated stereotactic boost as a part of their treatment plan are not eligible